FDA PCAC Peptide Hearing July 2026 — BPC-157 TB-500 Semax Epitalon Review

What is the PCAC hearing and why does it matter?

The Pharmacy Compounding Advisory Committee (PCAC) is an independent panel of scientific and medical experts appointed by the FDA. On July 23 and 24, 2026, this committee will meet at the FDA's White Oak Campus in Silver Spring, Maryland to review seven peptides for potential inclusion on the Section 503A Bulk Drug Substances List.

Why this matters: The 503A Bulks List is the only legal pathway for compounding pharmacies to prepare these peptides for individual patients with a physician's prescription. If a peptide is not on this list, has no USP monograph, and is not part of an FDA-approved drug — it cannot be legally compounded in the USA.

For peptides like BPC-157 and Semax, the 503A Bulks List is the only route to legal clinical access. A positive PCAC recommendation followed by formal FDA rulemaking would restore the legal prescription pathway for millions of Americans seeking these compounds under physician supervision.

Important

A positive PCAC recommendation is not FDA approval. It begins formal rulemaking that includes a Notice of Proposed Rulemaking, a public comment period, and a final rule. This process takes additional months to complete. Category 1 status means the FDA does not intend to take enforcement action against licensed 503A pharmacies compounding that substance for individual patients with a valid prescription.

The 7 peptides under review — what you need to know

Day 1 — July 23, 2026

Four peptides reviewed on Day 1

BPC-157 (free base and acetate)

FDA use under evaluation: Ulcerative colitis

Category 2 removed — awaiting Category 1 reclassification

BPC-157 is the most widely researched repair peptide in the compounding world. Derived from a protein in human gastric juice, it has been studied for gut healing, tissue repair, tendon recovery, and neuroprotection. Over 300 published papers document its preclinical profile.

Positive outcome

Licensed 503A compounding pharmacies could legally prepare BPC-157 for patients with a valid physician prescription. Patients could access pharmaceutical-grade BPC-157 with quality controls, endotoxin testing, and accurate dosing.

Negative outcome

BPC-157 would remain outside the compounding framework. Patients seeking it would continue to rely on gray-market RUO sources without quality guarantees.

KPV (free base and acetate)

FDA use under evaluation: Wound healing and inflammatory conditions

Category 2 removed — awaiting Category 1 reclassification

KPV is a tripeptide fragment of alpha-MSH with potent anti-inflammatory properties. One of the few peptides with genuine oral bioavailability, making it uniquely valuable for gut-targeted research. Studied for IBD, Crohn's disease, and wound healing.

Positive outcome

Oral and injectable KPV could be legally compounded by licensed pharmacies. Particularly significant for gut inflammatory condition research given its oral bioavailability.

Negative outcome

KPV remains outside compounding framework. Gray-market access only.

TB-500 (free base and acetate)

FDA use under evaluation: Wound healing

Category 2 removed — awaiting Category 1 reclassification

TB-500 is a synthetic fragment of Thymosin Beta-4 that promotes systemic tissue repair through actin regulation and stem cell recruitment. Frequently researched in combination with BPC-157 as the Wolverine Stack for comprehensive injury recovery protocols.

Positive outcome

TB-500 could be legally compounded and prescribed. Opens the most researched injury recovery combination (with BPC-157) to the licensed pharmacy system.

Negative outcome

Remains RUO. Gray-market access only. The Wolverine Stack cannot be legally prescribed.

MOTS-c (free base and acetate)

FDA use under evaluation: Obesity and osteoporosis

Category 2 removed — awaiting Category 1 reclassification

MOTS-c is a mitochondria-derived peptide discovered in 2015 that acts as an exercise mimetic — activating metabolic pathways of physical activity. Studied for insulin sensitivity, metabolic health, and bone density. Levels naturally decline with age.

Positive outcome

MOTS-c could be legally compounded for metabolic and bone health applications under physician supervision.

Negative outcome

Remains RUO. Limited to gray-market access with no quality controls.

Day 2 — July 24, 2026

Three peptides reviewed on Day 2

Emideltide (DSIP — Delta Sleep-Inducing Peptide)

FDA use under evaluation: Opioid withdrawal, chronic insomnia, narcolepsy

Category 2 removed — awaiting Category 1 reclassification

Emideltide, commonly known as DSIP, is a nonapeptide originally isolated from rabbit brain during slow-wave sleep in 1977. It specifically promotes the deep restorative delta sleep phase. The FDA evaluation for opioid withdrawal is a particularly significant clinical application.

Positive outcome

Legal prescription access for sleep disorders and potentially opioid withdrawal support — a significant public health application.

Negative outcome

Remains outside compounding framework.

Semax (free base and acetate)

FDA use under evaluation: Cerebral ischemia, migraine, trigeminal neuralgia

Category 2 removed — awaiting Category 1 reclassification

Semax is a synthetic analogue of ACTH(4-7) approved in Russia for stroke recovery and TBI. It stimulates BDNF and NGF production, increases cerebral blood flow, and penetrates the blood-brain barrier via intranasal administration. Among the most clinically studied neuropeptides globally outside the USA.

Positive outcome

Semax could be legally compounded as an intranasal preparation for neurological indications. Would bring a 40-year clinically validated compound into the US licensed pharmacy system.

Negative outcome

Remains outside US compounding framework. Patients continue to access through gray-market channels.

Epitalon (free base and acetate)

FDA use under evaluation: Insomnia

Category 2 removed — awaiting Category 1 reclassification

Epitalon is a tetrapeptide derived from the pineal gland, studied for telomere lengthening via telomerase activation and circadian rhythm regulation including sleep. Dr. Vladimir Khavinson published 40+ years of Russian research on this compound.

Positive outcome

Epitalon could be legally compounded for insomnia and sleep-related applications. Brings 40 years of international research into the US licensed system.

Negative outcome

Remains outside compounding framework.

How we got here — the complete regulatory timeline

2023

FDA moves 19 widely-used peptides to Category 2 overnight, effectively prohibiting compounding. Millions of Americans lose access to physician-supervised peptide therapy.

2024

Gray market expands dramatically. Patients turn to research-use-only vendors with no quality controls. Dr. Tatem describes this as "gas station sushi" — you don't know what you're getting.

February 2026

HHS Secretary RFK Jr. directs FDA to restore 14 peptides to Category 1. First major reversal of the 2023 restrictions.

April 15, 2026

FDA removes 12 peptides from Category 2 (Federal Register Doc. 2026-07361) and announces July 23-24 PCAC hearing for 7 of them. A second hearing for 5 more peptides announced before February 2027.

July 9, 2026

Public comment deadline. Comments submitted by this date are provided directly to the PCAC committee.

July 23-24, 2026

PCAC hearing at FDA White Oak Campus. The committee evaluates evidence and makes recommendations to the FDA Commissioner.

After the hearing

FDA decides whether to act on PCAC recommendations. Formal rulemaking process begins. Timeline to Category 1 addition: months to over a year.

February 2027

Second PCAC hearing for 5 additional peptides.

Your voice matters — how to submit a public comment

Comments submitted by July 9, 2026 will be provided directly to the PCAC committee reviewing these peptides.

Step 1: Go to the official FDA docket

federalregister.gov/d/2026-07361

This is the official Federal Register notice. Click the "Submit a Formal Comment" button on that page.

Step 2: Choose your comment type

Select 'Public Comment' from the submission options. You can submit as an individual — no medical or legal credentials required.

Step 3: What to include in your comment

The most effective comments include:

Your personal experience with or interest in these peptides
Why you believe access to physician-supervised compounded peptides matters
Any relevant professional perspective if applicable
Your support for the FDA restoring the legal prescription pathway

Keep it respectful, factual, and personal. Form letters carry less weight than individual personal accounts.

Step 4: Submit before July 9, 2026

Comments submitted by July 9 go directly to the committee. Comments submitted between July 9-22 are still reviewed by the FDA but may not reach the committee before the hearing.

ThePeptide.expert does not endorse specific positions on FDA regulatory matters. We provide this guide as an educational public service so our community understands how to participate in the public comment process. Participation in FDA comment processes is a fundamental right of every American citizen.

FDA PCAC Hearing — July 2026

What is the PCAC hearing and why does it matter?

The 7 peptides under review — what you need to know

Four peptides reviewed on Day 1

Three peptides reviewed on Day 2

How we got here — the complete regulatory timeline

Your voice matters — how to submit a public comment

Step 1: Go to the official FDA docket

Step 2: Choose your comment type

Step 3: What to include in your comment

Step 4: Submit before July 9, 2026

Download the complete PCAC 2026 guide

Hearing updates

Go deeper